ArticleFrontiers in immunology2026
Case Report: Diagnosis and detection of amoxicillin-induced immune hemolytic anemia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially severe adverse reaction, with antibiotics being common culprits. Amoxicillin, a widely used β-lactam antibiotic, has been infrequently reported to cause DIIHA, posing diagnostic challenges due to its nonspecific presentation. Objective: This study aimed to report a case of amoxicillin-induced DIIHA, detailing the diagnostic approach and laboratory methods for detecting drug-dependent antibodies. Methods: A 60-year-old female presented with jaundice, dark urine, and severe anemia following amoxicillin administration. Laboratory investigations included direct and indirect antiglobulin tests, antibody screening and identification, and drug-specific antibody detection using amoxicillin-sensitized red blood cells and drug-added assays. Clinical causality was assessed using the Naranjo Adverse Drug Reaction Probability Scale. Results: The patient's direct antiglobulin test was weakly positive for IgG without C3d activation. Serum showed pan-reactivity in saline, which resolved after dithiothreitol treatment, suggesting the presence of IgM cold antibodies. Serum reacted positively with amoxicillin-coated red cells in the indirect antiglobulin test but not with untreated cells, confirming the presence of amoxicillin-dependent antibodies. Hemoglobin and bilirubin levels improved after amoxicillin discontinuation. The Naranjo score was 7, indicating a "probable" association between amoxicillin and hemolysis. Conclusion: Amoxicillin can induce immune hemolytic anemia through a drug-dependent antibody mechanism. A combination of detailed drug history, serological testing, and drug-specific assays is essential for accurate diagnosis. Immediate withdrawal of the implicated drug remains critical for clinical recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.